Article: Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
AuthorsChung, ML1
Chi, LL1
See, CC1
Lau, GK1
Sheung, TF1
KeywordsActive immunization
Antibody against hepatitis B surface antigen
Immunity
Recurrence
Issue Date2005
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
CitationJournal Of Hepatology, 2005, v. 43 n. 2, p. 283-287 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2005.03.013
AbstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
ISSN0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
DOIhttp://dx.doi.org/10.1016/j.jhep.2005.03.013
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorChung, ML
dc.contributor.authorChi, LL
dc.contributor.authorSee, CC
dc.contributor.authorLau, GK
dc.contributor.authorSheung, TF
dc.date.accessioned2010-09-06T08:39:02Z
dc.date.available2010-09-06T08:39:02Z
dc.date.issued2005
dc.description.abstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Hepatology, 2005, v. 43 n. 2, p. 283-287 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2005.03.013
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2005.03.013
dc.identifier.epage287
dc.identifier.hkuros138679
dc.identifier.isiWOS:000230803900013
dc.identifier.issn0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
dc.identifier.issue2
dc.identifier.pmid15964658
dc.identifier.scopuseid_2-s2.0-21844435779
dc.identifier.spage283
dc.identifier.urihttp://hdl.handle.net/10722/83271
dc.identifier.volume43
dc.languageeng
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
dc.publisher.placeNetherlands
dc.relation.ispartofJournal of Hepatology
dc.relation.referencesReferences in Scopus
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, [VOL 43, ISSUE 2, 2005] DOI 10.1016/j.jhep.2005.03.013
dc.subject.meshHepatitis B Vaccines - administration and dosage - therapeutic use
dc.subject.meshHepatitis B virus - genetics - immunology
dc.subject.meshHepatitis B, Chronic - prevention and control - surgery - virology
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic use
dc.subject.meshVaccination
dc.subjectActive immunization
dc.subjectAntibody against hepatitis B surface antigen
dc.subjectImmunity
dc.subjectRecurrence
dc.titleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong